Melanoma

• 

  Subject Areas on Research

  • "Thin" malignant melanoma: risk factors and clinical management. 
  • (18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. 
  • 18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management. 
  • 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. 
  • A Case of Progressive Dimming Vision. 
  • A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. 
  • A PGC1β genetic variant associated with nevus count and melanoma mortality. 
  • A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. 
  • A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates. 
  • A comparison of dermatologists' and primary care physicians' accuracy in diagnosing melanoma: a systematic review. 
  • A complicated case of ciliary body melanoma and glaucoma. 
  • A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between CDC42 and SCIN genetic variants. 
  • A genomic- and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization. 
  • A global approach to tumor immunology. 
  • A histologic study (including DNA quantification and Ki-67 labeling index) in uveal melanomas after brachytherapy with ruthenium plaques. 
  • A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma. 
  • A methodology for utilization of predictive genomic signatures in FFPE samples. 
  • A model for pretest probability of lymph node metastasis from cutaneous Melanoma. 
  • A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion. 
  • A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. 
  • A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. 
  • A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. 
  • A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion. 
  • A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. 
  • A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. 
  • A multiphase immunotherapy regimen for human melanoma: clinical and laboratory results. 
  • A natural history of melanoma: serial gene expression analysis. 
  • A panel of antibodies useful in the cytologic diagnosis of metastatic melanoma. 
  • A patient with newly diagnosed melanoma and pulmonary nodules. 
  • A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. 
  • A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. 
  • A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. 
  • A phase I trial of human gamma interferon transduced autologous tumor cells in patients with disseminated malignant melanoma. 
  • A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation. 
  • A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2. 
  • A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma. 
  • A role for hepatic metastasectomy in stage IV melanoma and breast cancer: reestablishing the surgical modality. 
  • A systematic review of clinical outcomes for patients diagnosed with skin cancer spinal metastases. 
  • A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. 
  • A variant in FTO shows association with melanoma risk not due to BMI. 
  • ASO Author Reflections: Adjuvant Therapy is Effective for Melanoma Patients with Positive Sentinel Lymph Node Biopsy Who Forgo Completion Lymphadenectomy. 
  • ASO Author Reflections: Gene Expression-Profiling and Implications for Adjuvant Therapy in Melanoma. 
  • Abnormalitieis of monocyte chemotaxis in patients with melanoma: effects of immunotherapy and tumor removal. 
  • Absence of estrogen receptor in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody. 
  • Accurate identification of proliferative index in melanocytic neoplasms with Melan-A/Ki-67 double stain. 
  • Acoustic radiation force impulse imaging of the abdomen: demonstration of feasibility and utility. 
  • Acral Melanomas of the Sole May Have Worse Prognosis Compared with Other Sites of Acral Melanoma. 
  • Acral melanoma: a review of 185 patients with identification of prognostic variables. 
  • Active-specific immunization against melanoma: is the problem at the receiving end? 
  • Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: Pigmented Lesion Subcommittee consensus statement. 
  • Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. 
  • Adjuvant Therapy is Effective for Melanoma Patients with a Positive Sentinel Lymph Node Biopsy Who Forego Completion Lymphadenectomy. 
  • Adjuvant high-dose interferon therapy for high-risk melanoma. 
  • Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. 
  • Adoptive transfer and specific active immunization of patients with malignant melanoma. 
  • Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens. 
  • Advances in the care of the patient with malignant melanoma. 
  • Advances in the management of conjunctival melanoma. 
  • Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. 
  • Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. 
  • Age as a prognostic factor in the malignant melanoma population. 
  • An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1. 
  • An acrochordon-like melanoma metastasis. 
  • An immunopathologic study of retinoblastoma protein. 
  • An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. 
  • Analysis of 945 cases of pulmonary metastatic melanoma. 
  • Analysis of lymphocytic infiltration in uveal melanoma. 
  • Analysis of prognosis and disease progression after local recurrence of melanoma. 
  • Analysis of prognostic variables which influence early and long-term response of pet animal tumors to radiation alone and radiation plus heat. 
  • Anorectal melanoma: clinical characteristics and results of surgical management in twenty-four patients. 
  • Anorectal melanoma: clinical characteristics and the role of abdominoperineal resection. 
  • Anterior Chamber Angle Invasion of Iridociliary Melanoma. 
  • Antibody-induced release of cellular proteinases: loss of adhesion of human melanoma cells after binding of anti-melanoma antibody. 
  • Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma. 
  • Application of a panel of antiganglioside monoclonal antibodies to cytologic specimens. 
  • Application of posterior neck dissection in treating malignant melanoma of the posterior scalp. 
  • Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions? 
  • Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. 
  • Assessment of immunological techniques in the diagnosis and prognosis of ocular malignant melanoma. 
  • Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. 
  • Association between a rare novel TP53 variant (rs78378222) and melanoma, squamous cell carcinoma of head and neck and lung cancer susceptibility in non-Hispanic Whites. 
  • Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk. 
  • Association between putative functional variants in the PSMB9 gene and risk of melanoma--re-analysis of published melanoma genome-wide association studies. 
  • Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. 
  • Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. 
  • Associations between smoking behavior-related alleles and the risk of melanoma. 
  • Atypical cellular blue nevi (cellular blue nevi with atypical features): lack of consensus for diagnosis and distinction from cellular blue nevi and malignant melanoma ("malignant blue nevus"). 
  • Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression. 
  • Autoantibodies against cell surface GRP78 promote tumor growth in a murine model of melanoma. 
  • Autofluorescence of choroidal melanoma in 51 cases. 
  • Autofluorescence of orange pigment overlying small choroidal melanoma. 
  • Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab. 
  • Autologous bone marrow transplantation and factor XII, factor VII, and protein C deficiencies. Report of a new association and its possible relationship to endothelial cell injury. 
  • Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma. 
  • B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. 
  • B-lymphocytes from melanoma patients and normal individuals react with melanoma cells but also with irrelevant antigens. 
  • BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. 
  • BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. 
  • BRAF in melanoma: current strategies and future directions. 
  • Bayesian estimation of survival functions under stochastic precedence. 
  • Benefits to patient care of electronically capturing patient-reported outcomes in dermatology. 
  • Benign nodal nevi frequently harbor the activating V600E BRAF mutation. 
  • Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma. 
  • Bilateral pulmonary nodules in a 37-year-old woman with malignant melanoma. Pulmonary Langerhans cell histiocytosis (eosinophilic granuloma). 
  • Biopsy of a Choroidal Melanoma Using Transvitreal Pars Plana Vitrectomy. 
  • Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculature. 
  • Brief communication: melanoma-specific antibodies produced in monkeys by immunization with human melanoma cell lines. 
  • Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma. 
  • C-reactive protein as a marker of melanoma progression. 
  • CD34 expression in desmoplastic melanoma. 
  • CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy. 
  • CHOROIDAL TUMOR BIOPSY: A Review of the Current State and a Glance Into Future Techniques. 
  • CORRELATION OF GENE EXPRESSION PROFILE STATUS AND AMERICAN JOINT COMMISSION ON CANCER STAGE IN UVEAL MELANOMA. 
  • COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 
  • CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. 
  • CYLD inhibits melanoma growth and progression through suppression of the JNK/AP-1 and β1-integrin signaling pathways. 
  • Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment? 
  • Can chorio-retinal biopsy be justified? 
  • Can completion lymph node dissection be avoided for a positive sentinel node in melanoma? 
  • Can surgeons improve survival in stage IV melanoma? 
  • Cancer and pregnancy: the clinician's perspective. 
  • Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award. 
  • Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. 
  • Cancer in pregnancy: a review of the literature. Part I. 
  • Cancer incidence among patients of the U.S. Veterans Affairs Health Care System. 
  • Caspase 3 promotes surviving melanoma tumor cell growth after cytotoxic therapy. 
  • Catabolism of radioiodinated murine monoclonal antibody F(ab')2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods. 
  • Cell binding and tumor inhibiting functions of a new antihuman melanoma murine monoclonal antibody. 
  • Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides. 
  • Central nervous system metastases in malignant melanoma. 
  • Changes in oligosaccharide chains of autoantibodies to GRP78 expressed during progression of malignant melanoma stimulate melanoma cell growth and survival. 
  • Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis. 
  • Characteristics of patients diagnosed with both melanoma and renal cell cancer. 
  • Characterization of CD8(-) HLA class I/epitope tetrameric complexes binding T cells. 
  • Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma. 
  • Characterization of a chimpanzee anti-human melanoma antiserum. 
  • Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. 
  • Characterization of melanoma cell membrane tumor-associated antigens using xenoserum, alloserum, and autoserum: I. immunofluorescence. 
  • Characterization of three restricted specificity monoclonal antibodies raised against the human glioma cell line D-54 MG. 
  • Chemoimmunotherapy of metastatic malignant melanoma. The Salpétrière Hospital (SOMPS) experience. 
  • Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. 
  • Chemokine receptors and melanoma metastasis. 
  • Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. 
  • Choroidal metastatasis from a neuroendocrine tumor masquerading as choroidal melanoma. 
  • Chromatophoromas and chromatophore hyperplasia in Pacific rockfish (Sebastes spp.). 
  • Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases. 
  • Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases: the Deborah Iverson, MD, Lectureship. 
  • Circulating tumor cells in melanoma patients. 
  • Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma. 
  • Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors. 
  • Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. 
  • Clinical applications of PET in oncology. 
  • Clinical applications of dendritic cell vaccines. 
  • Clinical correlates of NRAS and BRAF mutations in primary human melanoma. 
  • Clinical diagnosis of moles vs melanoma. 
  • Clinical experience with Tc-99m labeled (N2S2) anti-melanoma antibody fragments and single photon emission computed tomography. 
  • Clinical factors in the identification of small choroidal melanoma. 
  • Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. 
  • Clinicopathologic factors relating to surgical margins for cutaneous melanoma. 
  • Clinicopathologic study of 85 cases of melanoma of the female genitalia. 
  • Clinicopathological correlations in unilateral glaucoma. 
  • Clonal persistence and evolution during a decade of recurrent melanoma. 
  • Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. 
  • Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. 
  • Comparing in vivo pump-probe and multiphoton fluorescence microscopy of melanoma and pigmented lesions. 
  • Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions. 
  • Comparison of diagnostic and management sensitivity to melanoma between dermatologists and MelaFind: a pilot study. 
  • Comparison of the use and results of sentinel lymph node biopsy in children and young adults with melanoma. 
  • Complete remission seven years after treatment for metastatic malignant melanoma. 
  • Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. 
  • Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates. 
  • Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma. 
  • Computed tomography in the detection of abdominal metastases from malignant melanoma. 
  • Congenital malignant melanoma. 
  • Conjunctival melanoma. 
  • Contemporary Approaches to In-Transit Melanoma. 
  • Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. 
  • Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors. 
  • Correlation between initial and long-term responses of spontaneous pet animal tumors to heat and radiation or radiation alone. 
  • Correlation of novel ALKATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma. 
  • Critical Assessment of Clinical Prognostic Tools in Melanoma. 
  • Current immunotherapeutic strategies in malignant melanoma. 
  • Current management of melanoma. 
  • Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. 
  • Curricular factors associated with medical students' practice of the skin cancer examination: an educational enhancement initiative by the integrated skin exam consortium. 
  • Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • Cutaneous lymphatic drainage in patients with grossly involved nodal basins. 
  • Cutaneous melanoma of the head and neck. A review of 399 cases. 
  • Cyclocreatine inhibits stimulated motility in tumor cells possessing creatine kinase. 
  • Cytokinetic and molecular pharmacology studies of arabinosylcytosine in metastatic melanoma. 
  • Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells. 
  • D6.1, a murine antimelanoma monoclonal antibody from congenitally athymic nude mice immunized with purified melanoma tumor-associated antigen. 
  • DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. 
  • DNA ploidy of malignant melanoma determined by image cytometry of fresh frozen and paraffin-embedded tissue. 
  • DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma. 
  • DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. 
  • Dangerous liaisons: flirtations between oncogenic BRAF and GRP78 in drug-resistant melanomas. 
  • Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. 
  • Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial. 
  • Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy. 
  • Dematiaceous fungi mimicking a conjunctival melanoma. 
  • Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. 
  • Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. 
  • Detection and quantification of S-100 protein in ocular tissues and fluids from patients with intraocular melanoma. 
  • Detection of cytoplasmic S-100 protein in primary and metastatic intraocular melanomas. 
  • Development and characterization of melanoma cell lines established by fine-needle aspiration biopsy: advances in the monitoring of patients with metastatic melanoma. 
  • Diagnosis of a solitary cardiac metastasis from ocular melanoma. 
  • Diagnosis of metastatic malignant melanoma by fine needle aspiration biopsy: a clinical and pathologic correlation of 298 cases. 
  • Diagnosis of ocular surface lesions using ultra-high-resolution optical coherence tomography. 
  • Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. 
  • Diagnostic accuracy of whole slide imaging for cutaneous, soft tissue, and melanoma sentinel lymph node biopsies with and without immunohistochemistry. 
  • Diagnostic and Therapeutic Challenges. 
  • Differential expression of N-cadherin distinguishes a subset of metastasizing desmoplastic melanomas. 
  • Differential volatile signatures from skin, naevi and melanoma: a novel approach to detect a pathological process. 
  • Discussion. 
  • Dissecting the immune landscape of tumor draining lymph nodes in melanoma with high-plex spatially resolved protein detection. 
  • Distant cutaneous granulomas after bacille Calmette-Guérin immunotherapy for malignant melanoma: case for direct infection. 
  • Distributed Drug Discovery, Part 3: using D(3) methodology to synthesize analogs of an anti-melanoma compound. 
  • Do Largest Basal Tumor Diameter and the American Joint Committee on Cancer's Cancer Staging Influence Prognostication by Gene Expression Profiling in Choroidal Melanoma. 
  • Does the number of sentinel lymph nodes removed affect the false negative rate for head and neck melanoma? 
  • Dose de-escalation with gamma knife radiosurgery in the treatment of choroidal melanoma. 
  • Dual-wavelength pump-probe microscopy analysis of melanin composition. 
  • ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. 
  • Early macular morphological changes following plaque radiotherapy for uveal melanoma. 
  • Early melanoma detection: nonuniform dermoscopic features and growth. 
  • Early-stage melanoma and hematopoietic stem cell transplantation outcomes. 
  • Effect of Uveal Melanocytes on Choroidal Morphology in Rhesus Macaques and Humans on Enhanced-Depth Imaging Optical Coherence Tomography. 
  • Effect of health care delivery models on melanoma thickness and stage in a university-based referral center: an observational pilot study. 
  • Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. 
  • Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. 
  • Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. 
  • Effects of total-body digital photography on cancer worry in patients with atypical mole syndrome. 
  • Efficacy and Safety of Low-Dose Iodine Plaque Brachytherapy for Juxtapapillary Choroidal Melanoma. 
  • Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. 
  • Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size. 
  • Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. 
  • Efficacy of hyperthermic isolated limb perfusion for extremity-confined recurrent melanoma. 
  • Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma. 
  • Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma. 
  • Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. 
  • Endoscopic ultrasound-guided fine-needle aspiration of intrathoracic and intra-abdominal spindle cell and mesenchymal lesions. 
  • Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles. 
  • Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. 
  • Enzymatic susceptibility and spontaneous release of human melanoma tumor-associated antigens. 
  • Epidemiologic support for melanoma heterogeneity using the Surveillance, Epidemiology, and End Results Program. 
  • Epidemiologic support for melanoma heterogeneity using the surveillance, epidemiology, and end results program. 
  • Erythropoietin receptor contributes to melanoma cell survival in vivo. 
  • Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). 
  • Evaluation of Racial, Ethnic, and Socioeconomic Associations With Treatment and Survival in Uveal Melanoma, 2004-2014. 
  • Evaluation of new putative tumor markers for melanoma. 
  • Evolution of delayed resistance to immunotherapy in a melanoma responder. 
  • Examining the Incidence and Presentation of Melanoma in the Cardiothoracic Transplant Population. 
  • Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. 
  • Exonuclease 1 (EXO1) gene variation and melanoma risk. 
  • Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. 
  • Experimental trials of immunotherapy for malignant melanoma. 
  • Exploring the association between melanoma and glioma risks. 
  • Exploring the melanoma survivorship experience: a qualitative study. 
  • Expression of a melanoma-tumor-associated antigen as demonstrated by a monoclonal antibody (D6.1) in cytopathologic preparations of human tumor cells from effusions and needle aspirates. 
  • External ocular pigmentation. 
  • FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. 
  • Factors associated with elevated intraocular pressure in eyes with iris melanoma. 
  • Factors associated with time to surgery in melanoma: An analysis of the National Cancer Database. 
  • Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. 
  • Familial aggregation of melanoma, basal cell carcinoma, and gastric adenocarcinoma. 
  • Ferromagnetic hyperthermia and iodine 125 brachytherapy in the treatment of choroidal melanoma in a rabbit model. 
  • Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. 
  • Fine needle aspiration biopsy of metastatic melanoma. 
  • Fine needle aspiration biopsy of metastatic melanoma. A morphologic analysis of 174 cases. 
  • Fine-needle aspiration of choroidal melanoma metastatic to the liver. 
  • Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines. 
  • Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT. 
  • Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy. 
  • Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study. 
  • Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients. 
  • FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients. 
  • Frailty models with missing covariates. 
  • Freckles, moles, and melanomas. 
  • Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. 
  • Functional Variants in Notch Pathway Genes NCOR2, NCSTN, and MAML2 Predict Survival of Patients with Cutaneous Melanoma. 
  • Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. 
  • Future directions in regional treatment strategies for melanoma and sarcoma. 
  • GD3 expression by cultured human tumor cells of neuroectodermal origin. 
  • Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines. 
  • Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma. 
  • Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. 
  • Gene variants in angiogenesis and lymphangiogenesis and cutaneous melanoma progression. 
  • Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. 
  • Generation of autologous tumor-specific cytotoxic T-cells using HLA-A region matched allogeneic melanoma. 
  • Generation of human IgG, IgA, and IgM anti-melanoma monoclonal antibodies utilizing lymphocytes of an actively immunized melanoma patient. 
  • Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. 
  • Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells. 
  • Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells. 
  • Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. 
  • Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. 
  • Genetic variants in ELOVL2 and HSD17B12 predict melanoma-specific survival. 
  • Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival. 
  • Genetic variants in PDSS1 and SLC16A6 of the ketone body metabolic pathway predict cutaneous melanoma-specific survival. 
  • Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. 
  • Genetic variants in TKT and DERA in the nicotinamide adenine dinucleotide phosphate pathway predict melanoma survival. 
  • Genetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival. 
  • Genetic variants in the PIWI-piRNA pathway gene DCP1A predict melanoma disease-specific survival. 
  • Genetic variants in the calcium signaling pathway genes are associated with cutaneous melanoma-specific survival. 
  • Genetic variants in the folate metabolic pathway genes predict cutaneous melanoma-specific survival. 
  • Genetic variants in the genes encoding rho GTPases and related regulators predict cutaneous melanoma-specific survival. 
  • Genetic variants in the integrin signaling pathway genes predict cutaneous melanoma survival. 
  • Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. 
  • Genetic variants in the vitamin D pathway genes VDBP and RXRA modulate cutaneous melanoma disease-specific survival. 
  • Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. 
  • Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. 
  • Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. 
  • Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. 
  • Genome-wide association study identifies nidogen 1 (NID1) as a susceptibility locus to cutaneous nevi and melanoma risk. 
  • Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. 
  • Genome-wide association study identifies three new melanoma susceptibility loci. 
  • Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. 
  • Genomic Classification of Cutaneous Melanoma. 
  • Genomic and molecular profiling predicts response to temozolomide in melanoma. 
  • Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. 
  • Glycoconjugates and tumor metastasis. 
  • HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. 
  • HLA-B7 associated tuberculin hyporesponsiveness in BCG treated melanoma patients. 
  • Hand metastasis from melanoma: a case study. 
  • Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. 
  • Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy. 
  • Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. 
  • Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF. 
  • High-Dose Interleukin-2: Evaluation of a Standardized Order Set for Biotherapy in an Intensive Care Unit
. 
  • High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity. 
  • High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. 
  • High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. 
  • High-fidelity mRNA amplification for gene profiling. 
  • High-field MR microscopy using fast spin-echoes. 
  • High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. 
  • Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma. 
  • Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma. 
  • Hoping for the best and preparing for the worst: a forgotten maxim in the immunotherapy era? 
  • Human T cells specifically activated against autologous malignant melanoma. 
  • Human cytotoxic T cells specific for autologous melanoma cells: successful generation from lymph node cells in seven consecutive cases. 
  • Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity. 
  • Human fetal brain antigen expression common to tumors of neuroectodermal tissue origin. 
  • Human melanoma and leukemia associated antigens difined by nonhuman primate antisera. 
  • Human melanoma cell migration along capillary-like structures in vitro: a new dynamic model for studying extravascular migratory metastasis. 
  • Human melanoma growth in the peritoneal cavity of the athymic mouse--a model for in vivo study of cell-mediated immunity. 
  • Human melanoma-mediated inhibition of autologous CD4+ helper tumor-infiltrating lymphocyte growth in vitro. 
  • Hydroxychloroquine-induced hyperpigmentation: the staining pattern. 
  • Hypoxia in melanoma: using optical spectroscopy and EF5 to assess tumor oxygenation before and during regional chemotherapy for melanoma. 
  • IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. 
  • Identification of a melanoma susceptibility locus and somatic mutation in TET2. 
  • Identification of a secreted Mr 95,000 glycoprotein in human melanocytes and melanomas by a melanocyte specific monoclonal antibody. 
  • Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV. 
  • Imaging microscopic pigment chemistry in conjunctival melanocytic lesions using pump-probe laser microscopy. 
  • Imaging of iris lesions with high-speed optical coherence tomography. 
  • Immune Checkpoint Inhibitors for Brain Metastases. 
  • Immune response of chimpanzee to purified melanoma 250 kilodalton tumor-associated antigen. 
  • Immune selection after antigen-specific immunotherapy of melanoma. 
  • Immunodiagnosis of melanoma using chimpanzee antihuman melanoma antiserum. 
  • Immunodiagnosis of tumors in vivo using radiolabeled monoclonal antibody A2B5. 
  • Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. 
  • Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma. 
  • Immunotherapy for malignant melanoma with a tumor cell vaccine. 
  • Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. 
  • Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells. 
  • Implications of leukoregulin to autologous tumor-specific human T-cell populations. 
  • Importance of sentinel lymph node biopsy in patients with thin melanoma. 
  • Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. 
  • Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. 
  • In vitro determination of thymidine-3H labeling index in human solid tumors. 
  • In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. 
  • In vivo evaluation of cell mediated immunity against human melanoma. 
  • In vivo label-free photoacoustic flow cytography and on-the-spot laser killing of single circulating melanoma cells. 
  • In vivo tumor localization using tumor-specific monkey xenoantibody, alloantibody, and murine monoclonal xenoantibody. 
  • In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. 
  • In-transit melanoma: the role of alkylating-agent resistance in regional therapy. 
  • Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. 
  • Independent predictors for local recurrence following surgery for spinal metastasis. 
  • Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. 
  • Influence of mouse hepatitis virus on the growth of human melanoma in the peritoneal cavity of the athymic mouse. 
  • Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. 
  • Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. 
  • Inhibition of SUR1 decreases the vascular permeability of cerebral metastases. 
  • Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma. 
  • Inhibition of the growth of human melanoma xenografts in nude mice by human tumor-specific cytotoxic T-cells. 
  • Injectable Therapies for Regional Melanoma. 
  • Integrated pathway and epistasis analysis reveals interactive effect of genetic variants at TERF1 and AFAP1L2 loci on melanoma risk. 
  • Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. 
  • Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment. 
  • Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. 
  • Interferon-mediated protection of B16 melanoma cells from cytotoxicity by activated macrophages. 
  • International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. 
  • Intracerebral malignant melanoma: high-field-strength MR imaging. 
  • Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment. 
  • Intraoperative 4-Dimensional Microscope-Integrated Optical Coherence Tomography-Guided 27-Gauge Transvitreal Choroidal Biopsy for Choroidal Melanoma. 
  • Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. 
  • Intrathoracic metastasis from an extrathoracic malignancy: a radiographic approach to patient evaluation. 
  • Intravitreal triamcinolone acetonide for acute radiation papillopathy. 
  • Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. 
  • Investigative studies in the diagnosis and treatment of melanoma. 
  • Investment in new technology research can save future health care dollars. 
  • Involvement of the TCL5 gene on human chromosome 1 in T-cell leukemia and melanoma. 
  • In vitro and in vivo evaluation of resveratrol and 3,5-dihydroxy-4'-acetoxy-trans-stilbene in the treatment of human prostate carcinoma and melanoma. 
  • Iris cyst secondary to latanoprost mimicking iris melanoma. 
  • Iris cyst secondary to latanoprost mimicking iris melanoma. 
  • Iris melanoma: risk factors for metastasis in 169 consecutive patients. 
  • Isolated limb infusion as a model to test new agents to treat metastatic melanoma. 
  • Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. 
  • Isolated metastatic melanoma to the colon mimicking colon cancer. 
  • Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. 
  • Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. 
  • Joint effect of multiple common SNPs predicts melanoma susceptibility. 
  • Juvenile malignant melanoma of the head and neck. 
  • Juvenile malignant melanoma. 
  • KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas. 
  • Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome. 
  • Kinetics of TCR use in response to repeated epitope-specific immunization. 
  • Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. 
  • Label-Free Imaging of Female Genital Tract Melanocytic Lesions With Pump-Probe Microscopy: A Promising Diagnostic Tool. 
  • Laparoscopic skill assessment of practicing surgeons prior to enrollment in a surgical trial of a new laparoscopic procedure. 
  • Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases. 
  • Late recurrence of malignant melanoma. Analysis of 168 patients. 
  • Lentigo maligna melanoma of the head and neck. 
  • Lethal "thin" malignant melanoma. Identifying patients at risk. 
  • Local control and distant metastases in primary canine malignant melanomas treated with hyperthermia and/or radiotherapy. 
  • Local control and results of Leksell Gamma Knife therapy for the treatment of uveal melanoma. 
  • Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study. 
  • Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. 
  • Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. 
  • Long-term follow-up after uveal melanoma charged particle therapy. 
  • Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. 
  • Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. 
  • Lymphatic mapping and sentinel lymphadenectomy in primary cutaneous melanoma. 
  • Lymphoscintigraphy for malignant melanoma. Surgical considerations. 
  • Lymphoscintigraphy in malignant melanoma: 99mTc antimony sulfur colloid. 
  • MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21. 
  • MEK inhibition in the treatment of advanced melanoma. 
  • MGSA/GRO transcription is differentially regulated in normal retinal pigment epithelial and melanoma cells. 
  • MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. 
  • MOLECULAR PROGNOSTICS FOR UVEAL MELANOMA. 
  • Macrophage migratory dysfunction in cancer. A mechanism for subversion of surveillance. 
  • Magnetic resonance imaging of juxtapapillary plaques in cadaver eyes. 
  • Malignant melanoma and pregnancy. 
  • Malignant melanoma and pregnancy. 
  • Malignant melanoma arising during pregnancy. A study of 100 patients. 
  • Malignant melanoma in black American and white American populations. A comparative review. 
  • Malignant melanoma in black Americans. A trend toward improved survival. 
  • Malignant melanoma in children. 
  • Malignant melanoma in the American black. 
  • Malignant melanoma in the elderly. 
  • Malignant melanoma induces migration and invasion of adult mesenchymal stem cells. 
  • Malignant melanoma metastatic to the gastrointestinal tract. 
  • Malignant melanoma of the conjunctiva. 
  • Malignant melanoma of the mucous membranes: a review of 119 cases. 
  • Malignant melanoma presenting as a mediastinal mass. 
  • Malignant melanoma with a myxoid stroma: a diagnostic pitfall on fine-needle aspiration biopsy. 
  • Malignant melanoma. Its prognosis as influenced by therapy. 
  • Malignant transformation of iris melanocytoma to iris ring melanoma. 
  • Management of recurrent melanoma of the extremity. 
  • Management strategies of academic pigmented lesion clinic directors in the United States. 
  • Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. 
  • Massive Extraocular Extension of Uveal Melanoma. 
  • Massive extraocular extension as the presenting feature of a choroidal melanoma. 
  • Mechanism of immune response during immunotherapy. 
  • Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. 
  • Melanocytic tumors with intraepidermal melanophages: a report of five cases with review of 231 archived cutaneous melanocytic tumors. 
  • Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness. 
  • Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. 
  • Melanoma arising in a skin graft. 
  • Melanoma brain metastasis: overview of current management and emerging targeted therapies. 
  • Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. 
  • Melanoma metastasis masquerading as bilateral acoustic neuromas. 
  • Melanoma of the ear: treatment and survival probabilities based on 199 patients. 
  • Melanoma of the foot. 
  • Melanoma of the gallbladder: a review of cases seen at Duke University Medical Center. 
  • Melanoma outcomes for Medicare patients: association of stage and survival with detection by a dermatologist vs a nondermatologist. 
  • Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies. 
  • Melanoma patients evaluated by four different positron emission tomography reconstruction techniques. 
  • Melanoma quality of life: pilot study using utility measurements. 
  • Melanoma reporting to central cancer registries by US dermatologists: an analysis of the persistent knowledge and practice gap. 
  • Melanoma underreporting among US dermatopathologists: A pilot study. 
  • Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. 
  • Melanoma, a tumor based on a mutant stem cell? 
  • Melanoma, version 4.2014. 
  • Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. 
  • Melanoma-associated retinopathy: a presenting sign of metastatic disease. 
  • Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. 
  • Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy. 
  • Melanoma. 
  • Melanomas of Unknown Primary May Have a Distinct Molecular Classification to Explain Differences in Patient Outcomes. 
  • Melanomas that defy clinical recognition. 
  • Melastatin expression and prognosis in cutaneous malignant melanoma. 
  • Meta-analysis of number needed to treat for diagnosis of melanoma by clinical setting. 
  • Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. 
  • Metabolic landscape of the tumor microenvironment at single cell resolution. 
  • Metastatic choroidal melanoma to the contralateral orbit 40 years after enucleation. 
  • Metastatic ciliary body carcinoid tumor. 
  • Metastatic malignant melanoma with an unknown primary. 
  • Metastatic melanoma in the thorax: report of 130 patients. 
  • Metastatic melanoma of gastrocolic ligament treated with minimally invasive approach. 
  • Metastatic melanoma to the heart. 
  • Metastatic melanoma to the spine. Demographics, risk factors, and prognosis in 114 patients. 
  • Metastatic vs primary malignant neoplasms affecting the umbilicus: clinicopathologic features of 77 tumors. 
  • Methods of Melanoma Detection. 
  • MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference. 
  • MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. 
  • Microsurgical composite tissue transplantation: a method of immediate reconstruction of the head and neck. 
  • Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion. 
  • Misleading aspiration biopsy in combined intraocular pathology. 
  • Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells. 
  • Modeling cancer progression via pathway dependencies. 
  • Modification of integrin-mediated cell attachment to substrata by serine proteinases in the presence and absence of divalent cations. 
  • Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. 
  • Modulation of in vitro autologous melanoma-specific cytotoxic T-cell responses by phorbol dibutyrate and ionomycin. 
  • Modulation of resistance to regional chemotherapy in the extremity melanoma model. 
  • Molecular alternations in uveal melanoma. 
  • Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma. 
  • Molecular classification of cutaneous malignant melanoma by gene expression profiling. 
  • Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. 
  • Molecular staging of malignant melanoma: correlation with clinical outcome. 
  • Monoclonal antibodies to human primary uveal melanomas demonstrate tumor heterogeneity. 
  • Monoclonal antibodies to uveal melanoma. 
  • Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature. 
  • Mucosal melanoma of the female genitalia: a clinicopathologic study of forty-three cases at Duke University Medical Center. 
  • Mucosal melanoma of the head and neck. 
  • Mucosal melanoma. 
  • Multi-center analysis of intraocular biopsy technique and outcomes for uveal melanoma: Ocular Oncology Study Consortium report 4. 
  • Multidrug resistance in ocular melanoma. 
  • Multifocal iris melanoma in a 2-year-old managed with I-125 plaque brachytherapy. 
  • Multiple assay characterization of murine monoclonal antimelanoma antibodies. 
  • Multiple lung nodules in a woman with a history of melanoma. 
  • Multiple primary melanoma: incidence and risk factors in 283 patients. 
  • Multivariate procedures to describe clinical staging of melanoma. 
  • Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. 
  • Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. 
  • Mutational signatures of de-differentiation in functional non-coding regions of melanoma genomes. 
  • Mutations of the BRAF gene in human cancer. 
  • Myocardial ischemia associated with high-dose carmustine infusion. 
  • Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients. 
  • NCCN Guidelines Insights: Melanoma, Version 3.2016. 
  • NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. 
  • Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy. 
  • Natural and orthogonal model for estimating gene-gene interactions applied to cutaneous melanoma. 
  • Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. 
  • Neoadjuvant use of ipilimumab in locally advanced melanoma. 
  • Neovascular glaucoma associated with an iris melanoma. A clinicopathologic report. 
  • Neurofibromatosis and neural crest neoplasms: primary acquired melanosis and malignant melanoma of the conjunctiva. 
  • New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma. 
  • Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. 
  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. 
  • Nivolumab: Immunotherapy in Malignant Melanoma. 
  • No association between Parkinson disease alleles and the risk of melanoma. 
  • Nodal Recurrence as Primary Driver of Early Relapse in Patients with SLN-Positive Melanoma: What Does It Mean for Providers and Patients? 
  • Non-specific and specific active immunotherapy in a B16 murine melanoma system. 
  • Non-specific and specific immunotherapy in patients with melanoma. 
  • Nonlinear microscopy of eumelanin and pheomelanin with subcellular resolution. 
  • Nonsynonymous somatic mitochondrial mutations occur in the majority of cutaneous melanomas. 
  • Novel enriched pathways in superficial malignant peripheral nerve sheath tumours and spindle/desmoplastic melanomas. 
  • Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. 
  • Nursing care of patients undergoing isolated limb procedures for recurrent melanoma of the extremity. 
  • Obesity-related genetic variants, human pigmentation, and risk of melanoma. 
  • Ocular Argyrosis Mimicking Conjunctival Melanoma. 
  • Ocular melanoma in a Long Evans rat. 
  • Ocular neoplastic disease. 
  • On the interplay of telomeres, nevi and the risk of melanoma. 
  • Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract. 
  • Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. 
  • Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. 
  • Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? 
  • Optimizing regional infusion treatment strategies for melanoma of the extremities. 
  • Optimizing regional therapy for melanoma. 
  • Outcomes of 27-Gauge Vitrectomy-Assisted Choroidal and Subretinal Biopsy. 
  • Outcomes of patients with a pretransplant history of early-stage melanoma. 
  • Overcoming MCL-1-driven adaptive resistance to targeted therapies. 
  • Overview of melanoma vaccines and promising approaches. 
  • PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. 
  • PGC-1 coactivators regulate MITF and the tanning response. 
  • PHGDH amplification and altered glucose metabolism in human melanoma. 
  • POT1 mutation spectrum in tumour types commonly diagnosed among POT1-associated hereditary cancer syndrome families. 
  • Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization. 
  • Paraganglioma-like dermal melanocytic tumor: a unique entity distinct from cellular blue nevus, clear cell sarcoma, and cutaneous melanoma. 
  • Paraneoplastic retinopathy with multiple detachments of the neurosensory retina and autoantibodies against interphotoreceptor retinoid binding protein (IRBP) in cutaneous melanoma. 
  • Patient education: recommendations regarding sunscreens, drugs, and diet. 
  • Patterns of GRP78 and MTJ1 expression in primary cutaneous malignant melanoma. 
  • Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. 
  • Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma. 
  • Pediatric conjunctival melanoma arising from a compound nevus. 
  • Pediatric melanoma. 
  • Pediatric melanoma: a single-institution experience of 150 patients. 
  • Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. 
  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. 
  • Perinatal Considerations in Women With Previous Diagnosis of Cancer. 
  • Perineural spread of melanoma demonstrated by F-18 FDG PET With MRI and pathologic correlation. 
  • Perineural tumor extension to the cavernous sinus from superficial facial carcinoma: CT manifestations. 
  • Periocular triamcinolone for prevention of macular edema after iodine 125 plaque radiotherapy of uveal melanoma. 
  • Periocular triamcinolone for prevention of macular edema after plaque radiotherapy of uveal melanoma: a randomized controlled trial. 
  • Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI. 
  • Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. 
  • Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. 
  • Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. 
  • Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report. 
  • Phase I study of melphalan alone and melphalan plus whole body hyperthermia in dogs with malignant melanoma. 
  • Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. 
  • Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. 
  • Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). 
  • Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). 
  • Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. 
  • Pigmented Iridociliary Lesion and Increased Intraocular Pressure. 
  • Pigmented Lesions of the Nervous System and the Neural Crest: Lessons From Embryology. 
  • Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion. 
  • Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. 
  • Polymorphisms of nucleotide excision repair genes predict melanoma survival. 
  • Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. 
  • Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. 
  • Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. 
  • Positron emission tomography scanning in malignant melanoma. 
  • Possibilities of immunotherapy and gene therapy for malignant melanoma. 
  • Precision Medicine and PET/Computed Tomography in Melanoma. 
  • Predicting disease progression after regional therapy for in-transit melanoma. 
  • Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. 
  • Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. 
  • Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. 
  • Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. 
  • Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide. 
  • Prevention and early detection of melanoma: a surgeon's perspective. 
  • Primary chondroid melanoma. 
  • Primary intracranial melanoma presenting as a suprasellar tumor. 
  • Primary intramedullary melanocytoma of the spinal cord: case report. 
  • Primary malignant melanoma of the esophagus. 
  • Primary malignant melanoma of the scrotum. 
  • Probing skin pigmentation changes with transient absorption imaging of eumelanin and pheomelanin. 
  • Prognosis for recurrent stage I malignant melanoma. 
  • Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. 
  • Prognostic factors in head and neck melanoma. Effect of lesion location. 
  • Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas. 
  • Progressive enlargement of cavity within melanoma masquerading as iris cyst. 
  • Proliferation indices correlate with diagnosis and metastasis in diagnostically challenging melanocytic tumors. 
  • Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases. 
  • Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. 
  • Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. 
  • Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. 
  • Prospects for cellular immunotherapy for metastatic melanoma. 
  • Proton-beam irradiated epithelioid cell melanoma of the ciliary body. 
  • Pseudomelanomas after conservative management of uveal melanoma. 
  • Pseudoprogression of Metastatic Melanoma to the Orbit With Pembrolizumab. 
  • Pulmonary metastasectomy for metastatic malignant melanoma. 
  • Pump-probe imaging differentiates melanoma from melanocytic nevi. 
  • Punch biopsy vs. shave biopsy: a comparison of margin status of clinically atypical pigmented lesions. 
  • Quality of life after isolated limb infusion for in-transit melanoma of the extremity. 
  • Quantifying melanin spatial distribution using pump-probe microscopy and a 2-D morphological autocorrelation transformation for melanoma diagnosis. 
  • Quiescent phenotype of tumor-specific CD8+ T cells following immunization. 
  • RELATIONSHIP OF CLINICAL FEATURES AND BASELINE TUMOR SIZE WITH GENE EXPRESSION PROFILE STATUS IN UVEAL MELANOMA: A Multi-institutional Study. 
  • Radiologic, endoscopic and surgical considerations of malignant melanoma metastatic to the small intestine. 
  • Radiologic, endoscopic, and surgical considerations of melanoma metastatic to the gastrointestinal tract. 
  • Radionuclide lymphoscintigraphy with technetium 99m antimony sulfide colloid to identify lymphatic drainage of cutaneous melanoma at ambiguous sites in the head and neck and trunk. 
  • Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. 
  • Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma. 
  • Randomized trial of hyperthermia and radiation for superficial tumors. 
  • Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. 
  • Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA-A2. 
  • Recommendations for the reporting of tissues removed as part of the surgical treatment of common malignancies of the eye and its adnexa. The Association of Directors of Anatomic and Surgical Pathology. 
  • Recurrent malignant melanoma of the penis. 
  • Recurrent malignant melanoma: the identification of prognostic factors to predict survival. 
  • Refractory myasthenia gravis exacerbation triggered By pembrolizumab. 
  • Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb. 
  • Regression of uveal melanoma after plaque radiotherapy and thermotherapy based on chromosome 3 status. 
  • Regulation of cell division and of tyrosinase in B16 melanoma cells by imidazole: a possible role for the concept of metabolite gene regulation in mammalian cells. 
  • Relationship between disease-free interval and survival in patients with recurrent melanoma. 
  • Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. 
  • Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. 
  • Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma. 
  • Retinal tear and detachment after transpupillary thermotherapy for choroidal melanoma. 
  • Retinal vasoproliferative tumors: surgical management and histological findings. 
  • Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma: A bi-institutional study. 
  • Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. 
  • Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins. 
  • Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. 
  • Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression. 
  • Role of cytogenetics in management of uveal melanoma. 
  • Role of surgical intervention in the management of intestinal metastases from malignant melanoma. 
  • Rural health disparities in melanoma staging and prognostic outcomes in Iowa. 
  • SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway. 
  • SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth. 
  • SPECT/CT: Looking Beyond Sentinel Lymph Node Identification for Improving Patient Outcomes. 
  • SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma. 
  • Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab. 
  • Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND): Report of a Prospective Multi-institutional Trial. 
  • Screening and prevention measures for melanoma: is there a survival advantage? 
  • Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study. 
  • Sector laser photocoagulation for the prevention of macular edema after plaque radiotherapy for uveal melanoma: a pilot study. 
  • Segmenting skin lesions with partial-differential-equations-based image processing algorithms. 
  • Segregation analysis in cutaneous malignant melanoma/dysplastic nevus syndrome families. 
  • Selection and validation of endogenous reference genes using a high throughput approach. 
  • Selection of patients with melanoma brain metastases for aggressive treatment. 
  • Selective inhibition of JNK with a peptide inhibitor attenuates pain hypersensitivity and tumor growth in a mouse skin cancer pain model. 
  • Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma. 
  • Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study. 
  • Sentinel lymph node biopsy following a rotational flap. 
  • Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. 
  • Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. 
  • Sentinel lymph node biopsy in melanoma of the head and neck. 
  • Sentinel lymph node biopsy is a prognostic measure in pediatric melanoma. 
  • Sentinel lymph node detection using laser-assisted indocyanine green dye lymphangiography in patients with melanoma. 
  • Sentinel node biopsy for head and neck melanoma: a systematic review. 
  • Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. 
  • Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity. 
  • Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. 
  • Sex related survival differences in instances of melanoma. 
  • Sex steroid receptor analysis in human melanoma. 
  • Short-term kinetics of tumor antigen expression in response to vaccination. 
  • Skeletal metastases of melanoma. 
  • Skin cancer in the military: A systematic review of melanoma and nonmelanoma skin cancer incidence, prevention, and screening among active duty and veteran personnel. 
  • Skin melanoma. Cured fraction and survival time as functions of thickness, site, histologic type, age, and sex. 
  • Small choroidal melanoma with chromosome 3 monosomy on fine-needle aspiration biopsy. 
  • Solitary pulmonary metastases in high-risk melanoma patients: a prospective comparison of conventional and computed tomography. 
  • Solubilization and partial isolation of human melanoma tumor-associated antigens. 
  • Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. 
  • Specific active immunotherapy for melanoma. 
  • Specific cytotoxic antibody in the sera of patients with melanoma. 
  • Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. 
  • Stage II malignant melanoma: presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients. 
  • Standardizing regional therapy: developing a consensus on optimal utilization of regional chemotherapy treatments in melanoma. 
  • Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. 
  • Statistical analysis of the concordance of immunohistochemical stains with the final diagnosis in spitzoid neoplasms. 
  • Status of activation of circulating vaccine-elicited CD8+ T cells. 
  • Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma. 
  • Studies of tumor-infiltrating lymphocytes from a human choroidal melanoma. 
  • Studies on the distribution of blood flow in amelanotic melanoma and reticulum cell lymphosarcoma during growth. 
  • Studies on the enhanced interaction of halodeoxyuridine-substituted DNAs with H1 histones and other polypeptides. 
  • Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin. 
  • Subungual melanoma. A review of 93 cases with identification of prognostic variables. 
  • Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. 
  • Supply-and-demand discrepancy in academic pigmented lesion clinics: a case for a new health care delivery model. 
  • Surgical management of aberrant sentinel lymph node drainage in cutaneous melanoma. 
  • Surgical management of cutaneous melanoma: current practice and impact on prognosis. 
  • Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. 
  • Surgical management of strabismus following choroidal melanoma plaque brachytherapy. 
  • Surgical management of the groin lymph nodes in melanoma in the era of sentinel lymph node dissection. 
  • Surgical margins around primary cutaneous melanomas. 
  • Surgical therapy of cutaneous melanoma. 
  • Surveillance strategies in the follow-up of melanoma patients: too much or not enough? 
  • Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. 
  • Survival is not the only valuable end point in melanoma screening. 
  • Survival superiority of females with melanoma. A multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. 
  • Swainsonine protects both murine and human haematopoietic systems from chemotherapeutic toxicity. 
  • Systematic identification of signaling pathways with potential to confer anticancer drug resistance. 
  • Systemic Therapies for Melanoma Brain Metastases: A Primer for Radiologists. 
  • T-cell-directed cancer vaccines: the melanoma model. 
  • Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. 
  • Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. 
  • Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. 
  • Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. 
  • Teenage acne and cancer risk in US women: A prospective cohort study. 
  • Telomere length connects melanoma and glioma predispositions. 
  • Temozolomide and treatment of malignant glioma. 
  • Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. 
  • The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. 
  • The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. 
  • The DNA repair capacity of melanoma cells. 
  • The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma. 
  • The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy. 
  • The Escherichia coli subtilase cytotoxin A subunit specifically cleaves cell-surface GRP78 protein and abolishes COOH-terminal-dependent signaling. 
  • The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma. 
  • The Linear Nail Streak: A Lesson in Cultural Humility. 
  • The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. 
  • The Skin Cancer Objective Structured Clinical Examination (SCOSCE): A multi-institutional collaboration to develop and validate a clinical skills assessment for melanoma. 
  • The State of Melanoma: Emergent Challenges and Opportunities. 
  • The annual risk of melanoma progression. Implications for the concept of cure. 
  • The changing landscape of dermatology practice: melanoma and pump-probe laser microscopy. 
  • The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. 
  • The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost. 
  • The efficacy of anti-PD-1 agents in acral and mucosal melanoma. 
  • The efficacy of full-lung tomography in the detection of early metastatic disease from melanoma. 
  • The fine structure of three malignant melanomas of the iris. 
  • The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. 
  • The identification and mapping of melanoma regional nodal metastases: minimally invasive surgery for the diagnosis of nodal metastases. 
  • The impact of shave biopsy on the management of patients with thin melanomas. 
  • The impact of total body photography on biopsy rate in patients from a pigmented lesion clinic. 
  • The limitations of imaging response criteria. 
  • The long-term clinical course of patients with cutaneous melanoma. 
  • The melanoma epidemic. Is increased surveillance the solution or the problem? 
  • The melanoma epidemic: more apparent than real? 
  • The orderly progression of melanoma nodal metastases. 
  • The prevalence and characteristics of congenital pigmented lesions in newborn babies in Oxford. 
  • The prognostic significance of recall antigen testing in melanoma patients. 
  • The rational clinical examination. Does this patient have a mole or a melanoma? 
  • The relationship between blood IL-12p40 level and melanoma progression. 
  • The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma. 
  • The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. 
  • The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma. 
  • The role of resection in the management of melanoma metastatic to the adrenal gland. 
  • The role of surgery for patients with metastatic melanoma. 
  • The role of whole brain radiation therapy in the management of melanoma brain metastases. 
  • The significance of glaucoma in the management of melanomas of the anterior segment. 
  • The spectrum of small bowel melanoma. 
  • The surgical management of metastatic melanoma. 
  • The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma. 
  • The trabecular wall of Schlemm's canal: a study of the effects of pilocarpine by scanning electron microscopy. 
  • The triangular intermuscular space as a site of lymph node metastasis in melanoma of the back. 
  • The tumor biology of melanoma nodal metastases. 
  • The tumor dormant state. 
  • The use of non-human primates for production of antisera to human tumor-associated antigens. 
  • The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation. 
  • Therapeutic and prognostic considerations of head and neck melanoma. 
  • Thin malignant melanomas of the head and neck. 
  • Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. 
  • Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. 
  • Time trends of incidence of age-associated diseases in the US elderly population: Medicare-based analysis. 
  • Timing of sentinel lymph node mapping after lymphoscintigraphy. 
  • To excise or not: impact of MelaFind on German dermatologists' decisions to biopsy atypical lesions. 
  • Towards a genomic-based diagnosis. 
  • Training High-Volume Melanoma Surgeons to Perform a Novel Minimally Invasive Inguinal Lymphadenectomy: Report of a Prospective Multi-Institutional Trial. 
  • Trametinib (GSK1120212) in the treatment of melanoma. 
  • Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumor immunity: a nude mouse model. 
  • Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity. 
  • Transected thin melanoma: Implications for sentinel lymph node staging. 
  • Transformation of cell type in uveal melanomas: a quantitative histologic analysis. 
  • Treatment of human melanoma hepatic metastases in nude mice with human cytotoxic T lymphocytes. 
  • Treatment of in-transit melanoma: an opportunity to discover critical knowledge. 
  • Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting. 
  • Tumor recognition and lytic competence of IL-2-activated lymphocytes: regulation of both antibody-independent and -dependent cellular cytotoxicity via P75 IL-2 receptor. 
  • Two-color, two-photon, and excited-state absorption microscopy. 
  • Two-day lymphoscintigraphic imaging for melanoma. 
  • Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma. 
  • UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling. 
  • Ultrastructural pathology of melanomalytic glaucoma. 
  • Ultrastructure and clinicopathologic correlation of idiopathic preretinal macular fibrosis. 
  • Unique Geospatial Accumulations of Uveal Melanoma. 
  • Unique proteins defined by monoclonal antibodies specific for human melanoma. Some potential clinical applications. 
  • Unraveling the molecular nature of melanin changes in metastatic cancer 
  • Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas. 
  • Updates in adjuvant systemic therapy for melanoma. 
  • Updates in imaging in ocular oncology. 
  • Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. 
  • Use of gene expression and pathway signatures to characterize the complexity of human melanoma. 
  • Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanoma. 
  • Using a continuous transformation of the Breslow thickness for prognosis in cutaneous melanoma. 
  • Utilization and rationale for the implementation of total body (digital) photography as an adjunct screening measure for melanoma. 
  • Uveal Melanoma Metastatic to the Cavernous Sinus: A Case Report. 
  • Uveal melanocytomas: genetic comparison with uveal and dermal melanomas. 
  • Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes. 
  • Uveal melanoma: updated considerations on current management modalities. 
  • Uveal prolapse following cataract extraction simulating melanoma. 
  • Validation of delayed sentinel lymph node mapping for melanoma. 
  • Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma. 
  • Variants in melanocortin 1 receptor gene contribute to risk of melanoma--a direct sequencing analysis in a Texas population. 
  • Variations in the ganglioside profile of uveal melanoma correlate with cytologic heterogeneity. 
  • Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. 
  • Virtual bronchoscopy for directing transbronchial needle aspiration of hilar and mediastinal lymph nodes: a pilot study. 
  • What is your diagnosis? Spitzoid melanoma. 
  • What's new in general surgery: surgical oncology. 
  • What's new in pediatric melanoma: An update from the APSA cancer committee. 
  • White Paper on Ophthalmic Imaging for Choroidal Nevus Identification and Transformation into Melanoma. 
  • Willingness-to-pay stated preferences for telemedicine versus in-person visits in patients with a history of psoriasis or melanoma. 
  • [Adjuvant therapy of surgically removed stage I melanoma]. 
  • [Basis for a specific-active immunotherapy in malignant melanoma]. 
  • [In vivo evaluation of cellular immunity in melanoma patients against melanoma]. 
  • [Longitudinal melanic nail bands (melanonychia): report of 22 cases]. 
  • [Malignant melanoma: hepatic intra-arterial chemotherapy]. 
  • alpha-Melanocyte-stimulating hormone-induced eruptive nevi. 
  • cDNA arrays and the enigma of melanoma immune responsiveness. 
  • p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. 
  • p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. 
• 

  Keywords of People

  • Bennett, Vann, George Barth Geller Distinguished Professor of Molecular Biology, Duke Cancer Institute
  • Hanks, Brent A., Associate Professor of Medicine, Pharmacology & Cancer Biology
  • Lee, Walter T, Professor of Head and Neck Surgery & Communication Sciences, Radiation Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Mosca, Paul Joseph, Associate Professor of Surgery, Surgical Oncology
  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, in the School of Medicine, Immunology
  • Yan, Hai, Henry S. Friedman Distinguished Professor of Neuro-Oncology in the School of Medicine, Pathology
  • Yoo, Sua, Associate Professor of Radiation Oncology, Radiation Oncology